Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Izanne Roos

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Pageof 8